All In Biotech

Drug Trial Radar · NCT04413552

INDV-2000 First in Human

A Phase I, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Jul 6, 2020

Primary completion

Apr 13, 2021

Study completion Apr 13, 2021

Sponsor

Lead sponsor
Indivior Inc.Industry
Sponsor type
Industry
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single ascending dose (SAD) study conducted to identify the maximum tolerated dose (MTD) of INDV-2000. After completion of the SAD portion of the study and acceptable safety evaluation, a food-interaction, single-dose study under fed and fasted conditions will be conducted.

Conditions

  • Opioid Dependence

Interventions

  • INDV-2000Drug

    INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.

  • PlaceboDrug

    Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug to end of study participation for each cohort; 11 days in Part 1 and 7 days in Part II, Period 1 (fasted conditions) and 10 days in Part II, Period 2 (fed conditions).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences Clinical Kansas

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.